NasdaqGS:ICPT

Stock Analysis Report

Executive Summary

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases.

Snowflake

Fundamentals

High growth potential with mediocre balance sheet.

Share Price & News

How has Intercept Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

6.9%

NasdaqGS:ICPT

0.6%

US Biotechs

1.3%

US Market


1 Year Return

-42.0%

NasdaqGS:ICPT

-10.3%

US Biotechs

2.0%

US Market

ICPT underperformed the Biotechs industry which returned -10.8% over the past year.

ICPT underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

ICPTIndustryMarket
7 Day6.9%0.6%1.3%
30 Day7.7%-1.2%3.9%
90 Day-17.1%-0.1%3.4%
1 Year-42.0%-42.0%-9.5%-10.3%4.2%2.0%
3 Year-56.0%-56.0%7.1%3.5%47.2%37.6%
5 Year-72.1%-72.1%3.3%-1.7%60.5%42.9%

Price Volatility Vs. Market

How volatile is Intercept Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Intercept Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Intercept Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

Intercept Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Intercept Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.

Intercept Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Intercept Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

Intercept Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Intercept Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 20 analysts?

60.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Intercept Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

Intercept Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.

Intercept Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.

Intercept Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.

Intercept Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Intercept Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Intercept Pharmaceuticals performed over the past 5 years?

-10.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Intercept Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Intercept Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Intercept Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Intercept Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Intercept Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Intercept Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Intercept Pharmaceuticals's financial position?


Financial Position Analysis

Intercept Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Intercept Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Intercept Pharmaceuticals's level of debt (311.1%) compared to net worth is high (greater than 40%).

Unable to establish if Intercept Pharmaceuticals's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 1.5x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Intercept Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.

Unable to confirm if Intercept Pharmaceuticals has at least 1 year of cash runway based on growing free cash flows without relevant data.


Next Steps

Dividend

What is Intercept Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Intercept Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Intercept Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Intercept Pharmaceuticals has not reported any payouts.

Unable to verify if Intercept Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Intercept Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Intercept Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Intercept Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.6yrs

Average management tenure


CEO

Mark Pruzanski (51yo)

17.7yrs

Tenure

US$4,525,959

Compensation

Dr. Mark Pruzanski, M.D., founded Intercept Pharmaceuticals, Inc. in 2003 and has been its Chief Executive Officer and President since 2002. Dr. Pruzanski serves as the President and Chief Executive Office ...


CEO Compensation Analysis

Mark's remuneration is about average for companies of similar size in United States of America.

Mark's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.6yrs

Average Tenure

50yo

Average Age

The tenure for the Intercept Pharmaceuticals management team is about average.


Board Age and Tenure

4.5yrs

Average Tenure

59.5yo

Average Age

The tenure for the Intercept Pharmaceuticals board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$314,08630 Aug 19
Samsara BioCapital LLC
EntityCompany
Shares5,207
Max PriceUS$60.32
BuyUS$4,498,57724 Aug 19
Samsara BioCapital LLC
EntityCompany
Shares67,784
Max PriceUS$67.12
BuyUS$100,20014 May 19
Luca Benatti
EntityIndividual
Role
Member of the Board of Directors
Director
Shares1,200
Max PriceUS$83.50
SellUS$557,12107 Dec 18
Lisa Morrison
EntityIndividual
Role
Senior Key Executive
President of International
Shares5,000
Max PriceUS$113.22
SellUS$78,802,50003 Dec 18
Genextra S.p.A.
EntityCompany
Shares750,000
Max PriceUS$105.07
SellUS$152,80730 Nov 18
Christian Weyer
EntityIndividual
Role
Senior Key Executive
Executive Vice President of Research & Development
Shares1,343
Max PriceUS$113.78

Ownership Breakdown


Management Team

  • Mark Pruzanski (51yo)

    Founder

    • Tenure: 17.7yrs
    • Compensation: US$4.53m
  • Jerry Durso (51yo)

    Chief Operating Officer

    • Tenure: 2.6yrs
    • Compensation: US$3.19m
  • Chris Weyer (49yo)

    Executive Vice President of Research & Development

    • Tenure: 1.8yrs
  • Mark Vignola (42yo)

    Executive Director

    • Tenure: 0yrs
  • Ryan Sullivan (43yo)

    General Counsel & Secretary

    • Tenure: 1.6yrs
    • Compensation: US$3.24m
  • Sandip Kapadia (49yo)

    CFO, Treasurer & Principal Accounting Officer

    • Tenure: 3.2yrs
    • Compensation: US$1.88m
  • Lisa Morrison (51yo)

    President of International

    • Tenure: 3.2yrs
    • Compensation: US$1.93m
  • Gail Cawkwell (57yo)

    Senior Vice President of Medical Affairs

    • Tenure: 1.6yrs
    • Compensation: US$2.21m
  • Richard Kim (50yo)

    President of U.S. Commercial & Strategic Marketing

    • Tenure: 4.2yrs
  • David Ford (50yo)

    Chief Human Resources Officer

    • Tenure: 2.3yrs
    • Compensation: US$1.91m

Board Members

  • Glenn Sblendorio (63yo)

    Director

    • Tenure: 5.6yrs
    • Compensation: US$354.37k
  • Dan Welch (61yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$351.87k
  • Luca Benatti (58yo)

    Director

    • Tenure: 5.2yrs
    • Compensation: US$349.37k
  • Gino Santini (62yo)

    Lead Independent Director

    • Tenure: 1.6yrs
    • Compensation: US$359.37k
  • Mark Pruzanski (51yo)

    Founder

    • Tenure: 17.7yrs
    • Compensation: US$4.53m
  • Paolo Fundaro (45yo)

    Chairman of the Board

    • Tenure: 3.9yrs
    • Compensation: US$364.37k
  • Alan Hofmann

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Scott Friedman

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Massimo Pinzani

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Aldo Roda

    Member of the Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Intercept Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Intercept Pharmaceuticals, Inc.
  • Ticker: ICPT
  • Exchange: NasdaqGS
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.253b
  • Shares outstanding: 32.70m
  • Website: https://www.interceptpharma.com

Number of Employees


Location

  • Intercept Pharmaceuticals, Inc.
  • 10 Hudson Yards
  • 37th floor
  • New York
  • New York
  • 10001
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ICPTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2012
I4PDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2012
ICPT *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNOct 2012

Biography

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:15
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.